Want to see JP:206A full AI Analyst Report?
206A Stock Chart & Stats
¥160.00
-¥4.00(-1.25%)
At close: 4:00 PM EST
¥160.00
-¥4.00(-1.25%)
Day’s Range― - ―
52-Week Range¥125.00 - ¥279.00
Previous CloseN/A
Volume305.30K
Average Volume (3M)96.44K
Market Cap
¥5.96B
Enterprise Value¥2.99K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.56
Shares Outstanding36,989,000
10 Day Avg. Volume86,800
30 Day Avg. Volume96,443
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSharp recent revenue growth indicates that PRISM BioLab is expanding commercial or partnering activity and gaining traction for its drug-discovery programs. If this growth persists, it can broaden the company’s funding base and improve operating leverage as programs advance through development.
Debt-Free Balance SheetThe absence of reported debt reduces fixed financial obligations and refinancing exposure while preserving flexibility to fund research, partnerships, and development activities. This gives PRISM BioLab more resilience than a similarly loss-making company carrying substantial leverage.
Partnering And Licensing ModelA partnering and licensing model can let PRISM BioLab monetize discovery programs through upfront funding, research support, milestones, and royalties without relying solely on internally funded commercialization. This creates several potential revenue stages as candidates progress.
Bears Say
Persistent Operating LossesPersistent negative EBIT and net income show that revenue growth has not yet translated into a sustainable earnings model. Continued losses can constrain internally funded research, increase dependence on partnerships or financing, and make execution of the development pipeline more important.
Accelerating Cash BurnRecurring negative free cash flow and worsening operating cash flow indicate that the business is consuming cash while advancing its activities. If this pattern persists, PRISM BioLab may need additional funding or partner support, reducing flexibility and increasing execution risk.
Gross Margin CompressionMargin compression suggests that the recent rebound in revenue has not improved the economics of the business proportionately. With net margins still heavily negative, the company must control operating costs or improve revenue quality before growth can produce durable profitability.
PRISM BioLab Co. LTD News
206A FAQ
What was PRISM BioLab Co. LTD’s price range in the past 12 months?
PRISM BioLab Co. LTD lowest stock price was ¥125.00 and its highest was ¥279.00 in the past 12 months.
What is PRISM BioLab Co. LTD’s market cap?
PRISM BioLab Co. LTD’s market cap is ¥5.96B.
When is PRISM BioLab Co. LTD’s upcoming earnings report date?
PRISM BioLab Co. LTD’s upcoming earnings report date is Nov 13, 2026 which is in 57 days.
How were PRISM BioLab Co. LTD’s earnings last quarter?
PRISM BioLab Co. LTD released its earnings results on Aug 14, 2026. The company reported -¥6.56 earnings per share for the quarter.
Is PRISM BioLab Co. LTD overvalued?
According to Wall Street analysts PRISM BioLab Co. LTD’s price is currently Overvalued.
Does PRISM BioLab Co. LTD pay dividends?
PRISM BioLab Co. LTD does not currently pay dividends.
What is PRISM BioLab Co. LTD’s EPS estimate?
PRISM BioLab Co. LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRISM BioLab Co. LTD have?
PRISM BioLab Co. LTD has 36,989,000 shares outstanding.
What happened to PRISM BioLab Co. LTD’s price movement after its last earnings report?
PRISM BioLab Co. LTD reported an EPS of -¥6.56 in its last earnings report. Following the earnings report the stock price went down -1.19%.
Which hedge fund is a major shareholder of PRISM BioLab Co. LTD?
Currently, no hedge funds are holding shares in JP:206A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRISM BioLab Co. LTD
PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α-helix or β-turn peptides, which are essential for protein-protein interactions. Through its platform, PRISM aims to discover drugs for what were previously considered 'undruggable targets,' with a pipeline including candidates for cancer and fibrotic diseases.
Technical Analysis
StemRIM Inc.
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―